Company Background in Brief $PFE 20261218 30.0 CALL$ is one of the world’s largest biopharmaceutical companies, selling medicines and vaccines in oncology, immunology, rare disease and infectious disease. As COVID-related sales fade, the company is rebuilding growth through acquisitions such as Metsera and a deeper oncology pipeline. Why It's on the Watchlist (Key Growth Catalysts) Pfizer’s newer medicines are growing fast. Its newer medicines grew 18% in the second quarter and brought in about $3.2 billion. Two cancer drugs, Padcev and Lorbrena, led the way with growth of 23% and 37%. The patent worry is getting smaller. A patent stops other companies from selling cheap copies of a drug. Pfizer made deals with three gene

Company Background in Brief $Rubrik Inc.(RBRK)$ is a cloud-native cybersecurity and data resilience enterprise that protects global organizations against ransomware and data disruptions through its zero-trust architecture. Backed by strategic investors like Microsoft, the company has successfully transitioned its business model toward high-margin software-as-a-service subscriptions while integrating artificial intelligence to automate enterprise data security. Why It's on the Watchlist (Key Growth Catalysts) Rubrik continues to drive robust top-line expansion, anchored by accelerating subscription annual recurring revenue and a growing base of high-value enterprise clients generating over $100,000 in annual recurring revenue. The company's strateg

On 2026-09-30, $UMS(558.SI)$ UMS INTEGRATION was suspended, pending a major private placement announcement to raise RM450 million. SO, what is behind? Company Background in Brief UMS Integration Limited is a precision engineering and high-end semiconductor equipment manufacturing company dual-listed on SGX and Bursa Malaysia. Operating globally with key production facilities in Singapore, Malaysia, and the US, the group is a trusted partner to major industry giants like $Applied Materials(AMAT)$ Applied Materials, providing robust high-precision components and complex integrated systems. Why It's on the Watchlist (Key Growth Catalysts) The company recently announced a major proposed share placement to r

On 2026-09-28, $Geo Energy Res(RE4.SI)$ shows a strong gap up, with increased volume. SO, what is behind? Company Background in Brief Founded in 2008, Geo Energy Resources Ltd. is an investment holding company that serves major Asian energy and industrial markets through three core segments: Coal Mining (selling coal from its own operations), Coal Trading (reselling third-party coal), and Mining Services (providing mining contracting and project management). Why It's on the Watchlist (Key Growth Catalysts) Surging Sales Volume: 3Q2026, coal sales reached approximately 3.3 million tonnes, nearly matching the combined output of 3.6 million tonnes from the first two quarters. Favorable Pricing: Average Indonesian Coal Index (ICI4) prices for 4,200

While $NVIDIA(NVDA)$ gets all the headlines for AI chips, a massive shift is happening behind the scenes. Big tech companies (hyperscalers) are trying to cut costs. Instead of buying expensive, one-size-fits-all GPUs, they are turning to Custom ASICs—tailor-made chips built for specific AI tasks. Two players are leading this charge: $Broadcom(AVGO)$ and $Marvell Technology(MRVL)$ . But they offer two very different ways to play the AI boom. Get your free vouchers from linktr.ee/ChillOnSunday 🔵 Broadcom (AVGO): The Steady Compounder Broadcom dominates the AI custom chip market (holding roughly 60% to 80%) with giants like Google and Meta. It isn't just a chipmaker

Broadcom delivered strong Q3 numbers and mapped out massive multi-gigawatt custom AI chip orders across Anthropic, OpenAI, and Meta through 2028. However, an in-line near-term forecast triggered immediate post-earnings profit-taking, knocking shares down toward key chart support around $360. For options traders, this pullback creates defined-risk opportunities to monetize volatility rather than chasing momentum. Executive summary Achieved record Q3 revenue of $29.6 billion, up 86% year-over-year, driven by strong demand for AI accelerators and networking. Q3 GAAP operating income reached $16.0 billion; non-GAAP operating income was $20.1 billion, up 92% year-over-year. Q3 GAAP diluted EPS was $2.68; non-GAAP diluted EPS was $3.32, up 96% year-over-year. Free cash flow for Q3 was $13.7 bill

$AbbVie(ABBV)$ is a leading global biopharmaceutical company based in the United States. Ranked among the largest in the industry, it develops treatments across key areas including immunology, cancer, neurology, and aesthetics. Its major products include blockbuster medicines like Humira, Skyrizi, and Rinvoq for autoimmune conditions, cancer therapies like Imbruvica and Venclexta, mental health medication Vraylar, and Botox. The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.' In a long-term uptrend, but it is currently hitting a strong price ceiling at $260–$262. Momentum is slowing down, which suggests sellers are stepping in and could cause